Rhumbline Advisers Increases Stake in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Rhumbline Advisers increased its holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 8.8% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 217,119 shares of the life sciences company’s stock after purchasing an additional 17,628 shares during the quarter. Rhumbline Advisers owned 0.28% of Integra LifeSciences worth $6,327,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in IART. Blue Trust Inc. grew its position in Integra LifeSciences by 100.5% during the 2nd quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock worth $26,000 after acquiring an additional 444 shares during the last quarter. CWM LLC raised its stake in shares of Integra LifeSciences by 50.8% during the second quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock valued at $37,000 after acquiring an additional 425 shares during the last quarter. Valley National Advisers Inc. purchased a new stake in shares of Integra LifeSciences during the first quarter worth about $63,000. Allspring Global Investments Holdings LLC increased its holdings in Integra LifeSciences by 58.0% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 4,662 shares of the life sciences company’s stock valued at $136,000 after purchasing an additional 1,711 shares during the period. Finally, Northwest Investment Counselors LLC bought a new position in Integra LifeSciences during the 1st quarter valued at approximately $143,000. 84.78% of the stock is owned by institutional investors.

Integra LifeSciences Stock Performance

IART stock opened at $17.47 on Friday. The stock has a market capitalization of $1.36 billion, a PE ratio of 34.94, a price-to-earnings-growth ratio of 0.60 and a beta of 1.10. The company has a current ratio of 3.39, a quick ratio of 2.10 and a debt-to-equity ratio of 1.17. Integra LifeSciences Holdings Co. has a 12-month low of $16.96 and a 12-month high of $45.42. The stock’s 50 day simple moving average is $23.90 and its 200 day simple moving average is $28.53.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Monday, July 29th. The life sciences company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.01. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The company had revenue of $418.20 million for the quarter, compared to the consensus estimate of $413.07 million. During the same quarter in the prior year, the firm earned $0.71 earnings per share. The firm’s revenue for the quarter was up 9.7% compared to the same quarter last year. As a group, research analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on IART. BTIG Research reduced their target price on Integra LifeSciences from $22.00 to $20.00 and set a “sell” rating on the stock in a research note on Wednesday, August 28th. Citigroup reduced their price target on shares of Integra LifeSciences from $23.00 to $20.00 and set a “sell” rating on the stock in a research report on Thursday, August 22nd. JMP Securities cut their price objective on Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating on the stock in a research report on Tuesday, July 30th. Truist Financial decreased their target price on Integra LifeSciences from $32.00 to $26.00 and set a “hold” rating for the company in a research report on Tuesday, July 30th. Finally, Morgan Stanley upped their price target on Integra LifeSciences from $24.00 to $27.00 and gave the stock an “underweight” rating in a research note on Monday, July 15th. Four analysts have rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $28.63.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.